Tranexamic acid can reduce and improve haematoma expansion (HE) in adults with stroke due to intracerebral haemorrhage (ICH) when administered quickly, finds a recent study.
The research was presented at the American Stroke Association’s International Stroke Conference 2020.
The study named– Spot Sign and Tranexamic Acid on Preventing ICH Growth – Australasia Trial (STOP-AUST) — compared the effect of treatment using tranexamic acid and placebo in people with ICH within 4.5 hours of the onset of stroke.
The multicentre, randomised study involving 100 patients showed alleviation of haematoma when treated with the antifibrinolytic, tranexamic acid, especially when treated within 3 hours of the brain bleed.
Researchers analyzed brain CT scans of ICH patients who had contrast extravasation on CT angiography, and called “spot sign”.
The research calls for larger trials focused on patient outcomes for the administration of the therapy to enter routine clinical practice.
“Further trials using tranexamic acid are ongoing and focusing on ultra-early treatment – within 2 hours. This is where the greatest opportunity for intervention appears to be,” said Nawaf Yassi, MBBS, BSc, Ph D, trial investigator and consultant neurologist at the Royal Melbourne Hospital.
ICH is a severe form of acute stroke with a few treatment options. Tranexamic acid is currently used to treat or prevent excessive blood loss from trauma, heavy menstruation, nosebleeds and post-partum bleeding.
“Tranexamic acid is inexpensive, safe and widely available,” said Yassi. “Our results and others provide great impetus for further, focused research using this treatment.”